Abstract: The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+ T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.

Abstract: A substrate includes a first doped region having a first type dopant, and a second doped region having a second type dopant and adjacent to the first doped region. A stack is formed that includes first layers and second layers alternating with each other. The first and second layers each have a first and second semiconductor material, respectively. The second semiconductor material is different than the first semiconductor material. A mask element is formed that has an opening in a channel region over the second doped region. A top portion of the stack not covered by the mask element is recessed. The stack is then processed to form a first and a second transistors. The first transistor has a first number of first layers. The second transistor has a second number of first layers. The first number is greater than the second number.

Abstract: Methods and devices that provide a first fin structure, a second fin structure, and a third fin structure disposed over a substrate. A dielectric fin is formed between the first fin structure and the second fin structure, and a conductive line is formed between the second fin structure and the third fin structure.

Abstract: The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.

Abstract: The present invention provides a desiccant pouch for use with a face covering. In one embodiment the desiccant pouch has a desiccant layer having a first side and a second side, a filter layer attached to the first side of the desiccant layer, and a carrier attached to the second side of the desiccant layer. In another embodiment, the desiccant pouch has a desiccant layer having a first side and a second side, a first carrier attached to the first side of the desiccant layer, and a second carrier attached to the second side of the desiccant layer.

Abstract: A semiconductor structure includes a semiconductor substrate; fin active regions protruded above the semiconductor substrate; and a gate stack disposed the fin active regions; wherein the gate stack includes a high-k dielectric material layer, and various metal layers disposed on the high-k dielectric material layer. The gate stack has an uneven profile in a sectional view with a first dimension D1 at a top surface, a second dimension D2 at a bottom surface, and a third dimension D3 at a location between the top surface and the bottom surface, and wherein each of D1 and D2 is greater than D3.

Abstract: Systems and methods of generating electrical current from at least one photovoltaic cell are described herein. In some embodiments, a dual-cell arrangement of photovoltaic cells may be disposed on a face. Equal parts of a first photovoltaic cell and a second photovoltaic cell may be disposed on the face such that when a portion of the face is shaded, the first photovoltaic cell and the second photovoltaic cell receive substantially equal amounts of electromagnetic radiation. In some embodiments, the first photovoltaic cell and the second photovoltaic cell comprises a plurality of sub-cell connected in series and parallel to optimize the power output form the partially exposed cells.

Abstract: Various embodiments of the present disclosure are directed towards a method for forming an integrated chip. The method includes forming an epitaxial structure having a first doping type over a first portion of a semiconductor substrate. A second portion of the semiconductor substrate is formed over the epitaxial structure and the first portion of the semiconductor substrate. A first doped region having the first doping type is formed in the second portion of the semiconductor substrate and directly over the epitaxial structure. A second doped region having a second doping type opposite the first doping type is formed in the second portion of the semiconductor substrate, where the second doped region is formed on a side of the epitaxial structure. A plurality of fins of the semiconductor substrate are formed by selectively removing portions of the second portion of the semiconductor substrate.

Abstract: A catalyst for a catalytic ink includes a support particle and a metallic material supported on the support particle. The metallic material is diamminesilver hydroxide, a silver salt, a palladium salt, a gold salt, chloroauric acid, or combinations thereof. A catalytic ink obtained from the catalyst and use of the same to fabricate a conductive circuit are also disclosed.

Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.

Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.

Abstract: A recovery system of composite powder carrier in HPB municipal wastewater treatment includes a biochemical tank and a concentration tank. The composite powder carrier is added to the biochemical tank for biochemically treating on the wastewater. The mixed liquid is then made to flow into the concentration tank. The supernatant obtained after filtration is then discharged. The concentrated sludge is returned to the biochemical tank, and the excess concentrated sludge is transported to a separator. The separator separates the substances with large specific gravity from those having smaller specific gravity, and the substances with large specific gravity are recycled to the biochemical tank for reuse. Matter having smaller specific gravity is discharged. The separator can be used to separate the composite powder carriers for recycling, which improves the utilization rate of the composite powder carriers and reduces the operation cost of the HPB technology for wastewater treatment.

Abstract: The present invention relates to microbial carriers for wastewater treatment, and in particular, relates to an organic composite powder carrier and its application for strengthening biological denitrification in municipal wastewater treatment. The organic composite powder carrier is compounded by a microbial carrier with a relatively large equivalent particle size and an organic alternative carbon source in the form of ultrafine powder. The composite powder carrier in the present invention includes a dedicated organic alternative carbon source, such as polyhydroxyalkanoates (PHA). The organic alternative carbon source can exclude the competitive relationship between microorganisms to ensure that denitrifying bacteria exclusively obtain electron donors required for denitrification.

Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.

Abstract: A substrate includes a first doped region having a first type dopant, and a second doped region having a second type dopant and adjacent to the first doped region. A stack is formed that includes first layers and second layers alternating with each other. The first and second layers each have a first and second semiconductor material, respectively. The second semiconductor material is different than the first semiconductor material. A mask element is formed that has an opening in a channel region over the second doped region. A top portion of the stack not covered by the mask element is recessed. The stack is then processed to form a first and a second transistors. The first transistor has a first number of first layers. The second transistor has a second number of first layers. The first number is greater than the second number.

Abstract: Provided is an anti-INF-? antibody. Also provided are a composition comprising the antibody and a pharmaceutical application of the antibody in treating IFN-? mediated syndrome.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

Abstract: A cross-scale wide-spectrum particle size plugging formula granularity analysis method includes: performing a size classification on a plugging material of a plugging formula; obtaining a particle size distribution of the plugging material by performing procession on each particle plugging material via a laser granularity analysis method and an imaging granularity analysis method, according to difference sizes thereof; obtaining the particle size distribution of the plugging formula by a weighted summation way, according to a granularity interval and an addition of each particle plugging material.

Abstract: This invention provides a method applied for the new dynamic arc radiotherapy treatment planning to calculate an optimal arc angle. With this invention, an operator without rich experience is able to reach the expected low dose in lungs easily and quickly. This invention can not only estimate the distribution of low radiation dose in lungs but also reduce the shortcomings like consumption of time and inaccuracy caused by manual trial and error.

Abstract: There is provided a framework including systems and methods for analyzing skin parameters from images or videos showing skin. Using a series of Hierarchical Differential Image Filters (HDIF), it becomes possible to detect different skin features such as wrinkles, spots, and roughness. The hierarchical differential image filter computes two enhancements to an image showing skin at two different levels of enhancement, determines a differential image using the two enhancements and computes the skin analysis rating using the differential image. These skin ratings are comparably accurate to actual ratings by dermatologists.